Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- (-) Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- (-) Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- (-) Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Display Only
Showing 80 Results
NAMI Weighs in on Value Assessment and ICER Engagement
Andrew Sperling, Director of Legislative Advocacy for the National Alliance on Mental Illness (NAMI), caught up with NPC President Dan Leonard to chat about concerns raised by mental health advocates…
Where Are They Now: Checking In With Former NPC Intern Dan Danielson
Dan Danielson, MS, currently a senior clinical manager at Premera Blue Cross, participated in NPC’s pharmaceutical internship program in 1993. Mr. Danielson chatted with us to answer a few questions…
NPC Chief Science Officer Robert Dubois to Address Value in Personalized Medicine at 13th Annual Personalized Medicine Conference
At the 13th Annual Personalized Medicine Conference, hosted by the Personalized Medicine Coalition, NPC's Dr. Robert W. Dubois will explore why health care stakeholder viewpoints on the value of a…
IVI Introduces Transparent Approach for Value Assessment
The Innovation and Value Initiative (IVI) released its first assessment of treatments for rheumatoid arthritis using its new approach toward value assessment. NPC is still evaluating IVI’s new…
NPC in AJPB: Guiding Practices for Patient-Centered Value Assessment
In response to growing concerns about health care costs, during the past few years, we’ve seen an increase in the development and use of value assessment frameworks. A variety of physician, payer and…
Appropriate Value Assessment Entails A Broad Perspective Of Impact and A Comprehensive Use of Evidence
NPC Chief Science Officer and Executive Vice President Robert W. Dubois looks at recent publications that highlight the need to consider a societal perspective when assessing value and utilize real…
An Important Dialogue About Orphan Drugs
While it’s encouraging to see that the Institute for Clinical and Economic Review (ICER) began the conversation about the value of orphan drugs, treatments that are used for conditions affecting very…
NPC @ AcademyHealth Annual Research Meeting: What Do We Know about High-Deductible Health Plans?
NCP Health Policy Fellow Ilene L. Hollin, PhD, MPH, will moderate a panel, “What Do We Know about High-Deductible Health Plans and What Do We Need to Learn?” to discuss what we know – and don’t know …
NPC is Going to ISPOR’s 22nd Annual International Meeting – Are You?
NPC will be at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting, held May 20-24 in Boston, to lead issue panels and workshops,…
How Can We Improve Oncology Quality Measurement in Accountable Care?
NPC and Discern Health analyzed the current oncology quality measure landscape for 10 high-priority cancers, published in the white paper "Improving Oncology Quality Measurement in Accountable Care,"…
The Evolution of Value Assessment
A Health Affairs Blog post by NPC Chief Science Officer Robert Dubois, MD, PhD, and Vice President for Health Services Research Kimberly Westrich, MA, identified several key considerations that could…
How Is the Multiple Sclerosis Community Engaging on Value Assessment?
NPC President Dan Leonard caught up this week for a Q&A with Lisa Skutnik, President of the MS Coalition, to discuss how the value of multiple sclerosis (MS) treatments is being assessed,…
Missed Signals in Cancer Care: Strategies to Address Quality Measure Gaps
When it comes to designing accountable care models, the dramatically varied needs and preferences of patients with cancer can confound quality measurement, especially when compounded by increasingly…
Engaging With ICER: National Psoriasis Foundation Opens Up on Value Assessment
NPC President Dan Leonard chatted with Leah Howard, Vice President of Government Relations and Advocacy, National Psoriasis Foundation, about value assessment frameworks and how her organization is…